Inventor · disambiguated record
Robert Sikorski
Also filed as: SIKORSKI ROBERT · SIKORSKI ROBERT S
9 granted patents·14 pending applications·44 citations·filing 2015–2025
85Inventor score
Files withFIVE PRIME THERAPEUTICS INC15JASPER THERAPEUTICS INC3BLUEBIRD BIO INC1BOLT BIOTHERAPEUTICS INC1IMMUSOFT CORP1
Top patents by PatentIndex Score
23 records- 0195US9765147B2Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Sep 19, 2017·25 cites·31 claims
- 0292US10221244B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2017·Granted Mar 5, 2019·10 cites·31 claims
- 0388US10618967B2Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancerFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Apr 14, 2020·5 cites·31 claims
- 0481US2023212299A1Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0576US10730949B2Method of treating PVNS with anti-CSF1R antibodiesFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·1 cites·35 claims
- 0675US10040858B2Anti-CSF1R antibodies for treating PVNSFIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Aug 7, 2018·2 cites·56 claims
- 0771US11566076B2Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancersFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·25 claims
- 0869US2023052212A1Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0966US10975153B2Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2015·Granted Apr 13, 2021·1 cites·29 claims
- 1066US2025152714A1Migratory modified differentiated b cells for cancer therapyIMMUSOFT CORP·Filed 2024·Application pending·0 cites
- 1165US2023192870A1Combination Anti-CSF1R and Anti-PD-1 Antibody Combination Therapy for Pancreatic CancerFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1265US2025223367A1Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1360US2021009700A1Anti-CSF1R Antibodies for Treating PVNSFIVE PRIME THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1459US11421034B2Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancerFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Aug 23, 2022·0 cites·15 claims
- 1557US2021317219A1Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R)FIVE PRIME THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1656US11447553B2FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatmentFIVE PRIME THERAPEUTICS INC·Filed 2016·Granted Sep 20, 2022·0 cites·10 claims
- 1756US2025375524A1Combination of engineered natural killer (nk) cells and antibody therapy and related methodsINDAPTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1853US2024409603A1Modified stem cell compositions and methods for useJASPER THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1952US2023181733A1Compositions and methods for stem cell transplant conditioning and uses thereofJASPER THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2051US2023165968A1Cancer treatment methodsBOLT BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2148US2024115615A1Modified stem cell compositions and methods for useJASPER THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2238US2018147271A1Anti-ror1 chimeric antigen receptorsBLUEBIRD BIO INC·Filed 2016·Application pending·0 cites
- 2330US2017058025A1Methods of using anti-ang2 antibodiesMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Sikorski files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →